At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Rakesh Sahay discusses the challenges of management of patients living with type 2 diabetes. This is part two of his interview, part one can be viewed here.
1. Where do sulfonylureas fit into the current treatment paradigm for T2D? (0:04)
2. What are you most looking forward to at this year’s EASD? (2:37)
Rakesh Sahay is an Advisory board member to Sanofi, Novo, Lily
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
Share this Video
Related Videos In Diabetes
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Insulin at 100: a life-saving discovery but more remains to be done
2021 marks the centenary of the discovery of insulin. It is important to remind ourselves that this life-saving medication still remains beyond the reach of many people with diabetes who need it. Find out more at: https://worlddiabetesday.org/about/insulin-at-100/ Support: Published in collaboration with the International Diabetes Federation.
Juliana Chan, EASD 2020 – COVID-19 and type 1 diabetes
We spoke with Prof. Juliana Chan (The Chinese University of Hong Kong, Hong Kong) following her session on COVID-19 and the impact on patients with type 1 diabetes. Questions What key areas of diabetes and COVID-19 were discussed at EASD 2020? (0:05) How do you think the COVID-19 pandemic has affected treatment both now and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!